Advertisement
Starting July 1st, ANTHELIOS 40 will be available at select physicians'offices, CVS/pharmacy (at their pharmacy counters), Duane Reade, Longs andBrooks locations with Dermo-Skincare Centers, and online atwww.laroche-posayus.com.
Advertisement
Photosensitivity is a pervasive issue for people suffering from a varietyof photosensitive conditions including, but not limited to, PMLE,Photoallergic Eruption (sun allergies), Phototoxicity, Solar Uticaria (sunrashes) and autoimmune disease. In fact, it is estimated that up to 17% ofthe US population alone experience symptoms related to PMLE as a result of UV(primarily UVA) exposure(2). These figures are likely understated as manypotential patients do not seek treatment for proper diagnosis. Inapproximately 50% of those affected, the action spectrum is actually UVArays(3).
La Roche-Posay ANTHELIOS 40 is the new FDA approved sunscreen for outdoor-use that has the highest UVA and UVB protection available in a sunscreen withMexoryl(TM) SX to meet these needs. Having been tested for safety on specialpopulations including those with photosensitive skin, such as PMLE(4), thisformula provides a unique and synergistic combination of sun filters.
About ANTHELIOS 40
Innovation: A unique synergistic combination of sun filters. ANTHELIOS 40contains the highest concentration of Mexoryl(TM) SX, the organic, stable sunfilter designed to protect skin from the short UVA waves and provide enhancedoverall UVA protection. Mexoryl(TM) SX is particularly effective againstshort UVA waves and is a key ingredient in ensuring this essential completebroad-spectrum protection. Unlike many other sunscreen filters that offer UVAprotection, Mexoryl(TM) SX is highly photostable and has been shown tomaintain activity for up to five hours in laboratory testing. Thisbreakthrough innovation is the culmination of many years of research andtesting. The result is demonstrated efficacy and safety that is supported by87 non-clinical toxicology studies, 29 clinical studies (including 21 clinicalpharmacology studies) tested on over 2,500 patients. Mexoryl(TM) SX was firstpatented in 1982 in Europe by L'Oreal and has a long history of safety andefficacy studies worldwide. La Roche-Posay was the first to launchMexoryl(TM) SX in a sunscreen formula in Europe over 15 years ago and thenmost recently in the U.S. in 2006.
For the first time in the U.S., this FDA-approved, breakthroughformulation also combines 5% Titanium Dioxide (an inorganic sun filter) with2% Avobenzone (an organic sun filter) to provide an enhanced formulation withcomplete broad spectrum protection. No other company is able to provide thecombined UVA protective benefits of any physical blocker with stabilizedAvobenzone in one formula.
Finally, a patented stabilized combination of Avobenzone (Parsol 1789) andOctocrylene provide UVB and long UVA coverage.
With this synergistic combination of ingredients, ANTHELIOS 40 has thehighest UVA and UVB protection available in a sunscreen with Mexoryl(TM) SXfor those who are serious about sun protection. For outdoor use, it should beused as a key prevention tool against the risks associated with exposure toharmful UVA and UVB rays.
Benefits of ANTHELIOS 40: With the highest UVA and UVB protectionavailable in a sunscreen with Mexoryl(TM) SX, ANTHELIOS 40 follows the samestrict formulation charter representative of the La
